Browsing by Author "Robinson, Thompson G."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Influence of Including Patients with Premorbid Disability in Acute Stroke Trials: The HeadPoST Experience(2021) Wang, Xia; Moullaali, Tom J.; Ouyang, Menglu; Billot, Laurent; Sandset, Else Charlotte; Song, Lili; Delcourt, Candice; Hackett, Maree L.; Watkins, Caroline L.; Robinson, Thompson G.; Yang, Jie; Lavados, Pablo; Brunser, Alejandro; Muñoz Venturelli, Paula; Olavarría, Verónica; Arima, Hisatomi; Middleton, Sandy; Pontes-Neto, Octávio M.; Pandian, Jeyaraj Durai; Rogers; Rogers, Kris; Anderson, Craig S.Background: Patients with premorbid functional impairment are generally excluded from acute stroke trials. We aimed to determine the impact of including such patients in the Head Positioning in acute Stroke Trial (HeadPoST) and early additional impairment on outcomes. Methods: Post hoc analyses of HeadPoST, an international, cluster-randomized crossover trial of lying-flat versus sitting-up head positioning in acute stroke. Associations of early additional impairment, defined as change in modified Rankin scale (mRS) scores from premorbid levels (estimated at baseline) to Day 7 ("early ΔmRS"), and poor outcome (mRS score 3-6) at Day 90 were determined with generalized linear mixed model. Heterogeneity of the trial treatment effect was tested according to premorbid mRS scores 0-1 versus 2-5. Results: Of 8,285 patients (38.9% female, mean age 68 ± 13 years) with complete data, there were 1,984 (23.9%) with premorbid functional impairment (mRS 2-5). A significant linear association was evident for early ∆mRS and poor outcome (per 1-point increase in ΔmRS, adjusted odds ratio 1.20, 95% confidence interval 1.14-1.27; p < 0.0001). Patients with greater premorbid functional impairment were less likely to develop additional impairment, but their risk of poor 90-day outcome significantly increased with increasing (worse) premorbid mRS scores (linear trend p < 0.0001). There was no heterogeneity of the trial treatment effect by level of premorbid function. Conclusions: Early poststroke functional impairment that exceeded premorbid levels was associated with worse 90-day outcome, and this association increased with greater premorbid functional impairment. Yet, including premorbid impaired patients in the HeadPoST did not materially affect the subsequent treatment effect.Item Withdrawal of active treatment after intracerebral haemorrhage in the INTERACT2 study(2017) Muñoz Venturelli, Paula; Wang, Xia; Zahuranec, Darin B.; Lavados, Pablo; Stapf, Christian; Lindley, Richard; Delcourt, Candice; Chalmers, John; Anderson, Craig S.; Robinson, Thompson G.; THOMPSON G. ROBINSON8, THOMPSON G. ROBINSON8 , FOR THE INTERACT2 INVESTIGATORSBackground: in the second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2), a minority of patients received withdrawal of active treatment (WAT). We wished to determine the characteristics of these patients, and the relation of this decision-making to subsequent management and final outcome. Methods: the INTERACT2 cohort of acute intracerebral haemorrhage (ICH) patients had a decision of WAT within 7 days after hospital admission recorded. Multivariable logistic regression was used to identify the determinants of WAT and poor outcome at 90 days, defined by modified Rankin scale (mRS) scores 3–6. Results: of 2,779 participants with available data, WAT occurred in 121 (4%) and this was significantly associated with increasing age, greater neurological severity, larger haematoma volume, intraventricular extension and randomisation to intensive BP lowering. Compared to other patients, those with WAT had greater mortality (81/121 [67%] versus 205/2624 [8%]; P < 0.001) and survivors were more likely to be severely disabled (mRS score 4–5, 19/39 [49%] versus 695/2419 [29%]; P = 0.006). Conclusions: WAT was undertaken in patients with recognised predictors of poor prognosis, who subsequently were more likely to die or be left with severe disability. Improved understanding of specific factors determining WAT in ICH patients might improve care delivery and outcomes. Clinical Trial Registration: the INTERACT2 study is registered with ClinicalTrials.gov (NCT00716079).